The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.

Inclusion Criteria

• Subject is ≥7 years of age.
• Subject has a clinical diagnosis of type 1 diabetes for more than 1 year as determined via medical records or source documentation by an individual qualified to make a medical diagnosis.
• Subject has a HbA1c value greater than 6.5% and less than 12% at time of enrolment visit.
• Subject is under Continuous Subcutaneous Insulin Infusion (CSII) therapy (with or without Continuous Glucose Monitoring) ≥ 6 months before enrolment.
• Subject requires ≥8 units of insulin per day.
• Subjects and their parent(s)/guardian(s) must be able to speak and be literate in French as verified by the investigator.
• Subjects and their parent(s)/guardian(s) are willing to participate in the study and sign the Data Release Form (DRF).
• Subjects who are ≥18 years of age should be able to provide consent.

Exclusion Criteria

• Subject has MiniMed™ 780G System IFU contraindication(s).
• Subject uses Predictive Low-Glucose Management (PLGM) System (i.e. MiniMed™ 640G with SmartGuard) in the last 6 months before the enrolment.
• Subject uses Low Glucose suspend (LGS) feature (i.e. MiniMed™ Paradigm Veo Pump) in the last 6 months before the enrolment.
• Subject under Multiple-Daily Injections (MDI) treatment in the 6 months before the enrolment.
• Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).